Nakajima, Yuto
Tonegawa, Hitoshi
Noguchi-Sasaki, Mariko
Nogami, Keiji http://orcid.org/0000-0002-2415-2194
Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science and Technology (18K07885)
Article History
Received: 1 December 2020
Revised: 5 February 2021
Accepted: 18 February 2021
First Online: 26 February 2021
Compliance with ethical standards
:
: YN and KN receive research support from Chugai Pharmaceutical Co., Ltd. (Chugai), and are engaged in clinical studies sponsored by Chugai and F. Hoffmann-La Roche. KN receives (consulting) honoraria from these companies, and is an inventor of the patents relating to emicizumab. MN-S is an employee of Chugai. HT has no conflict of interest.